Skip to content

Remediation for Mild Cognitive Deficits After Cancer

EvalUation of REmediation Programs for Patients Suffering From Mild Cognitive Deficits After CAncer

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04808674
Acronym
EURECA
Enrollment
24
Registered
2021-03-22
Start date
2021-12-17
Completion date
2025-07-17
Last updated
2023-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer, Cognitive Remediation

Keywords

Neuropsychology, psychological distress, quality of life, rehabilitation

Brief summary

Cancer survival rates have improved significantly over the past decades and patients now experience a number of side effects including cancer-related cognitive impairment (CRCI): problems with memory, executive function, attention, and difficulties performing two tasks at the same time. The frequency of CRCI in cancer patients is estimated to be between 10 to 40%, and more than 50% of patients describe difficulties in their daily life. These cognitive difficulties negatively impact the patient's quality of life as well as that of their family, and can also have negative consequences for their social and professional reintegration once cancer treatment is finished. Despite an increasing number of studies on CRCI, a standard of care for patients with CRCI after breast cancer is yet to be established. In the absence of clear directives, and in an attempt to respond to the increasing demand to provide care for breast cancer patients with CRCI, physical medicine and rehabilitation units in France have started providing day-hospital multidisciplinary interventions. The objective of this project is to use the single case experimental design method to investigate the efficacy of two such rehabilitation programs: a group-based program and a one-on-one program.

Interventions

Evaluation of REmediation programs for patients suffering from mild cognitive deficits after Cancer

Sponsors

Hospices Civils de Lyon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Treated in the past for breast cancer with chemotherapy, surgery, and / or radiotherapy, * Admitted as a day patient at the Henry Gabrielle Hospital or the Pontchaillou CHU Hospital during the study, * Given free, informed consent in writing after being informed orally and in writing of the how the study will proceed.

Exclusion criteria

* Presence of another active cancer, * Ongoing chemotherapy and/or radiotherapy treatment, * Active progression of breast cancer, * History of neurological or psychiatric conditions, * Major disturbances in comprehension that prevent them giving free, informed consent, * Pregnant, parturient or breastfeeding women, * Person under a legal protection measure such as guardianship or curatorship, * People not affiliated to a social security scheme (French Social Security) or beneficiaries of a similar scheme.

Design outcomes

Primary

MeasureTime frameDescription
Self-reported cognitive function16 weeksThe Fact-COG questionnaire assesses subjective cognitive impairment. The score directly reflects the patient's feelings about/perceptions of their cognitive function over the previous week. A total score out of 132 is obtained as well as 4 subscales: Perceived Cognitive Impairments (0-72), Impact on Quality of Life (0-16), Comments from Others (0-16), and Perceived Cognitive Abilities (0-28).

Secondary

MeasureTime frameDescription
Neuropsychological function16 weeksNeuropsychological function will be measured using three sub-tests of the Test of Attentional Performance (alertness, covert shift of attention, divided attention), the Paced Auditory Serial Addition Test, the Montreal Cognitive neuropsychological Assessment, and the Symbol Digit Modalities Test.
Psychological distress16 weeksPsychological distress will be measured using 4 questionnaires: The Hospital Anxiety and Depression Scale; the Brief Symptom Inventory-18; the Rosenberg self-esteem scale; the MCQ-30 Meta-cognition self-report questionnaire.
Quality of Life with FACT-B questionnaire16 weeksThe FACT-B questionnaire assesses cancer-related quality of life. A total score out of 148 is obtained as well as 5 subscales: Physical Well-Being (0-28), Social/Family Well-Being (0-28), Functional-Well-Being (0-28), Emotional Well-Being (0-24), and Breast Cancer Subscale (0-40).
Fatigue16 weeksThe FACTIT-Fatigue questionnaire assesses fatigue/ tiredness and its impact on daily activities and functioning in chronic disease. A total score out of 52 is obtained.

Countries

France

Contacts

Primary ContactSophie JACQUIN-COURTOIS, PhD
sophie.courtois@chu-lyon.fr04.78.86.50.64
Backup ContactMélanie COGNÉ, MD
melanie.cogne@chu-rennes.fr02.99.28.42.18

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026